AnGes, Gene Design, BioMedical Research Institute (AIST), Osaka University deal

AnGes said it partnered with Gene Design, AIST and the university to develop AnGes’ oral NF-kappa B decoy to treat refractory inflammatory bowel disease (IBD). The compound is an oligonucleotide that blocks NF-kappa B ( NF-kB). AnGes said the deal may be expanded to include osteoarthritis (OA), rheumatoid arthritis (RA) and asthma. Details were not disclosed. ...